Skip to main content
Fig. 5 | BMC Nephrology

Fig. 5

From: Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

Fig. 5

Influence of modelled scenarios on predicted time to ESRD, relative to the base case analysis in which the treatment effect measured by reciprocal of serum creatinine was applied to the overall TEMPO 3:4 population, without discontinuation. White bars indicate model predictions under natural history; grey bars indicate the incremental effect of tolvaptan on predicted time to ESRD

Back to article page